Low molecular weight heparin vs no thromboprophylaxis: Major bleeding
- Population
- ambulatory cancer patients receiving chemotherapy
- Intervention
- Low molecular weight heparin
- Comparison
- no thromboprophylaxis
- Outcome
- Major bleeding
Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Low‐molecular‐weight heparin vs no thromboprophylaxis Major bleeding · ambulatory cancer patients receiving chemotherapy Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty). Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane Headline outcomes only | RR 1.63 [1.12, 2.35] | 15 studies · 7282 participants | Moderate |
Low molecular weight heparin vs no thromboprophylaxis Major bleeding · ambulatory cancer patients receiving chemotherapy Low molecular weight heparin showed no clear difference in major bleeding compared with no thromboprophylaxis (low certainty). Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2016) · Cochrane Headline outcomes onlyearlier version CD008500.PUB4, superseded | RR 1.44 [0.98, 2.11] | 13 studies · 6356 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Low molecular weight heparin vs vitamin K antagonist (VKA) · people with cancer with thrombosis prophylaxis and central venous catheters · 1 review
- Low molecular weight heparin vs active control · ambulatory cancer patients receiving chemotherapy · 1 review
- Low molecular weight heparin vs unfractionated heparin · patients with cancer with venous thromboembolism · 1 review
- Low molecular weight heparin vs UFH · patients with venous thromboembolism. · 1 review
- Low molecular weight heparin vs control · children with a CVC · 1 review
- Low molecular weight heparin vs no LMWH · people with cancer with thrombosis prophylaxis and central venous catheters · 1 review
- Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis · patients with cancer with venous thromboembolism · 1 review
- Low molecular weight heparin vs no prophylaxis · adults undergoing KA · 1 review
- Low molecular weight heparin vs vitamin K antagonist (VKA) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE · 1 review
- Low molecular weight heparin vs unfractionated heparin · adults with kidney failure treated with long‐term HD · 1 review
- Low molecular weight heparin vs UFH · patients with the initial treatment of venous thromboembolism in patients with cancer · 0 reviews
- Low molecular weight heparin vs UFH · People with cancer with perioperative thromboprophylaxis · 0 reviews
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.